Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
18 Results for "
PAFR Antagonist
" in MedChemExpress (MCE) Product Catalog:
Products (18)
18 Results for "PAFR Antagonist" in MCE Product Catalog:
3
Research Areas:
Apafant (WEB 2086), a chemical probe, is a potent platelet-activating factor (PAF) antagonist, inhibits PAF binding to human PAF receptors with a Ki of 9.9 nM. Apafant increases the gene expression of PAF-r, α-globin, β-globin, decreases the c-myb gene expression. Apafant shows a protective effect on alkyl-PAF-mediated lethalit .
3
Target:
Research Areas:
Rilapladib (SB 659032) is a selective Lp-PLA2 (lipoprotein-associated phospholipase A2) inhibitor with an IC50 of 230 pM . Rilapladib (SB 659032) is also a PAFR (Platelet Activating Factor Receptor) antagonist .
Cat. No.: HY-W700638A
CAS No.: 76166-55-7
Synonyms: AH 21-132
Research Areas:
Benafentrine maleate is a platelet activating factor receptor (PAFR) antagonist and a PDE 4 inhibitor .
Cat. No.: HY-177598
CAS No.: 123852-99-3
Research Areas:
F-0401 is a calcium antagonist with platelet-activating factor receptor (PAFR) antagonistic action. F-0401 can be used for the research of neurological disease, such as stroke .
Cat. No.: HY-132210
CAS No.: 116673-45-1
Research Areas:
rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane (compound 6) is a platelet-activating factor receptor (PAFR) antagonist with a Ki of 0.3 µM .
Cat. No.: HY-106899
CAS No.: 135947-75-0
Research Areas:
MK 287 is a potent, selective and orally active antagonist of platelet-activating factor receptor (PAFR). MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets in plasma or gel-filtered platelets and elastase release from PMNs with ED50 values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis .
Cat. No.: HY-121394
CAS No.: 113787-28-3
Research Areas:
L-659,989 is an orally active, extremely potent, selective and competitive platelet activating factor (PAF) receptor antagonist .
Cat. No.: HY-N3436
CAS No.: 99340-07-5
Cat. No.: HY-117636
CAS No.: 129314-27-8
Research Areas:
(Rac)-L-659989 is the racemate of L-659989 (HY-121394). L-659989 s an orally active, extremely potent, selective and competitive platelet activating factor (PAF) receptor antagonist .
Synonyms: UK-74505
Target:
Research Areas:
(Rac)-Modipafant (UK-74505) is an orally active, selective, long-acting irreversible platelet activating factor receptor (PAFR) antagonist. (Rac)-Modipafant prevents dengue infection .
Cat. No.: HY-134101
CAS No.: 78858-42-1
Research Areas:
2-O-Ethyl PAF C-16 is a homolog of PAF and a competitive ligand for PAF receptor (Platelet-activating Factor Receptor (PAFR)). 2-O-Ethyl PAF C-16 inhibits the binding of the PAF antagonist WEB 2086 (HY-108634) to the PAF receptor with an IC50 of 21 nM .
Cat. No.: HY-108634S
CAS No.: 1185101-22-7
Synonyms: WEB 2086-d8
Cat. No.: HY-106899A
CAS No.: 143445-03-8
Synonyms: (rel)-L-680573
Research Areas:
(rel)-MK 287 ((rel)-L-680573) is a relative configuration of MK 287. MK 287 is a potent, selective and orally active antagonist of platelet-activating factor receptor (PAFR). MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets in plasma or gel-filtered platelets and elastase release from PMNs with ED50 values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis .
Cat. No.: HY-19205A
CAS No.: 193739-23-0
Synonyms: LDP-392
Research Areas:
CMI-392 (LDP-392) is an orally active dual 5-lipoxygenase inhibitor and platelet-activating factor receptor (PAFR) antagonist, with an IC50 of 10 nM for human PAF receptor and an IC50 of 100 nM for rat 5-lipoxygenase. CMI-392 blocks PAF receptor binding, inhibits leukotriene synthesis, attenuates PAF-induced hemoconcentration, and suppresses arachidonic acid- and TPA-induced ear swelling in mice. CMI-392 reduces inflammatory cell infiltration, decreases MPO levels, alleviates ocular inflammation, and improves dextran sulfate sodium-induced colitis. CMI-392 can be used in the research of inflammatory and immune-related diseases such as colitis and atopic dermatitis .
Cat. No.: HY-108908R
CAS No.: 122956-68-7
Synonyms: UK-74505 (Standard)
Research Areas:
(Rac)-Modipafant (Standard) is the analytical standard of (Rac)-Modipafant (HY-108908). This product is intended for research and analytical applications. (Rac)-Modipafant (UK-74505) is an orally active, selective, long-acting irreversible platelet activating factor receptor (PAFR) antagonist. (Rac)-Modipafant prevents dengue infection .
Cat. No.: HY-102004R
CAS No.: 412950-08-4
Synonyms: SB 659032 (Standard)
Target:
Research Areas:
Rilapladib (Standard) is the analytical standard of Rilapladib (HY-102004). This product is intended for research and analytical applications. Rilapladib (SB 659032) is a selective Lp-PLA2 (lipoprotein-associated phospholipase A2) inhibitor with an IC50 of 230 pM . Rilapladib (SB 659032) is also a PAFR (Platelet Activating Factor Receptor) antagonist .
Cat. No.: HY-108634R
CAS No.: 105219-56-5
Synonyms: WEB 2086 (Standard)
Research Areas:
Apafant (Standard) is the analytical standard of Apafant (HY-108634). This product is intended for research and analytical applications. Apafant (WEB 2086), a chemical probe, is a potent platelet-activating factor (PAF) antagonist, inhibits PAF binding to human PAF receptors with a Ki of 9.9 nM. Apafant increases the gene expression of PAF-r, α-globin, β-globin, decreases the c-myb gene expression. Apafant shows a protective effect on alkyl-PAF-mediated lethalit .
Cat. No.: HY-19205B
CAS No.: 205654-37-1
Research Areas:
(2S,5S)-CMI-392 is the absolute configuration of CMI-392 (HY-19205A). CMI-392 is an orally active dual 5-lipoxygenase inhibitor and platelet-activating factor receptor (PAFR) antagonist, with an IC50 of 10 nM for human PAF receptor and an IC50 of 100 nM for rat 5-lipoxygenase. CMI-392 blocks PAF receptor binding, inhibits leukotriene synthesis, attenuates PAF-induced hemoconcentration, and suppresses arachidonic acid- and TPA-induced ear swelling in mice. CMI-392 reduces inflammatory cell infiltration, decreases MPO levels, alleviates ocular inflammation, and improves dextran sulfate sodium-induced colitis. CMI-392 can be used in the research of inflammatory and immune-related diseases such as colitis and atopic dermatitis .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
